10:07 AM EST - Oncolytics Biotech Inc : Reported on significant 2023 accomplishments and announced corporate priorities and anticipated clinical development milestones for 2024. "2023 was an outstanding year for Oncolytics and the development of pelareorep as a potential cancer therapy, said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. "We believe our cash balance and strong data, supported by our active business development program, position us well for 2024." Oncolytics Biotech Inc
shares T.ONC are trading up one cent at $1.77.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=8366990090871896
